Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C

Inclusion Criteria: * Age: 18\~65 years. * Pregnancy tests of female patients must be negative. All patients with effective birth control measures during treatment period and 6 months after the cessation of treatment. * Chronic HCV infection evidence: HCV RNA or anti-HCV positive \>6 months; liver biopsy evidence; vital signs, symptoms, exposure history, and results of laboratory test and iconography examination support diagnosis of chronic hepatitis C. * HCV RNA≥2000IU/ml. Exclusion Criteria: * Pregnant or lactating women. * Mental disorder or physical disability. * WBC\<3000/mm3, or ANC \<1500/mm3, or PLT \<90,000/mm3. * Received interferon treatment within the previous 6 months or shew no response to interferon. * Co-infection with HIV, HAV, HBV, HEV. * Evidence of hepatic decompensation. * Chest X-ray with clinically significant active inflammatory process, history of significant pulmonary disease or any history of interstitial lung disease. * History of hypothyroidism or current treatment for thyroid disease. * Diabetes mellitus. * Uncontrolled significant chronic medical conditions other than chronic hepatitis C or other conditions which in the opinion of the investigator preclude enrollment into the study.